Currently Viewing:
Supplements Pathways to Success: Utilizing Managed Care Models to Improve Clinical and Economic Outcomes in Diab
Current State of Type 2 Diabetes Management
Mark E. Molitch, MD
Economic Implications of Type 2 Diabetes Management
Carrie McAdam Marx, PhD, RPh
Optimizing Diabetes Management: Managed Care Strategies
E. Albert Tzeel, MD, MHSA
Currently Reading
Participating Faculty: Pathways to Success: Utilizing Managed Care Models to Improve Clinical and Economic Outcomes in Diabetes

Participating Faculty: Pathways to Success: Utilizing Managed Care Models to Improve Clinical and Economic Outcomes in Diabetes

This supplement to The American Journal of Managed Care provides an overview of the etiology and pathophysiology of type 2 diabetes mellitus (T2DM), including factors that contribute to suboptimal glucose control; explores current clinical practice guidelines and algorithms; evaluates new and emerging treatment strategies; and addresses managed care aspects of managing T2DM, including the impact of disease management programs on clinical measures, healthcare expenditures, and inpatient utilization.
Faculty

Carrie McAdam Marx, PhD, RPh
Research Associate Professor
Department of Pharmacotherapy
Pharmacotherapy Outcomes Research Center
University of Utah
Salt Lake City, Utah

Mark E. Molitch, MD
Martha Leland Sherwin Professor of Endocrinology
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

E. Albert Tzeel, MD, MHSA
National Medical Director
HumanaOne, Humana Inc.
Milwaukee, Wisconsin

Contributing Editorial Support

William Perlman, PhD, CMPP
Medical Director
Long Valley, NJ

Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Carrie McAdam Marx, PhD, RPh
Consultant/advisory board: GlaxoSmithKline, Novo Nordisk
Research grant: Bristol-Myers Squibb

Mark E. Molitch, MD
Consultant/advisory board: Abbott, Janssen, Lilly, Novartis, Novo Nordisk
Expert testimony: Janssen
Grants: Lilly, Novartis, Novo Nordisk, Sanofi

E. Albert Tzeel, MD, MHSA
Consultant/advisory board: Amylin Pharmaceuticals
Employment/stock ownership: Humana Inc

The American Journal of Managed Care
Publishing Staff—Jeff D. Prescott, PharmD, RPh; Kara Guarini, MS; and Ida Delmendo have no relevant financial relationships with commercial
interests to disclose.
 
PER and Pharmacy Times Office of Continuing Professional Education
Planning Staff—Judy V. Lum, MPA; Elena Beyzarov, PharmD; and Ann C. Lichti, CCMEP, have no relevant financial relationships with commercial interests to disclose.
 
PER and Pharmacy Times Office of Continuing Professional Education uses an anonymous peer review process to resolve conflicts of interest. The peer reviewers of this CME/CE activity have no relevant financial relationships with commercial interests to disclose.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up